HotSpot Therapeutics
PrivateLast Round
Series C
Nov 29, 2021
Total Funding Raised
$210M
Company Overview
HotSpot Therapeutics is a biotechnology company that pioneers allosteric drug discovery by identifying and targeting natural regulatory hotspots on proteins to develop differentiated small molecule medicines for autoimmune diseases and cancer.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
HotSpot Therapeutics Comparables
Compare HotSpot Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Exo Therapeutics | 85% | |
| Allorion Therapeutics | 84% | |
| Nimbus Therapeutics | 83% |
HotSpot Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Nov 29, 2021 | ||||
| Series B | May 21, 2020 | ||||
| Series A | Jul 17, 2018 |
Key People
Founding team and executive leadership
HotSpot Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Brace Pharma Capital | Series B |
| EQT Life Sciences | Series C |
| B Capital Group | Series C |
| Pivotal bioVenture Partners | Series C |
| Tekla Capital Management | Series B, Series C |
| Nan Fung Group | Series C |
| Solasta Ventures | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 4, 2026
Presented preclinical data at the 15th European Lupus Meeting.
- Mar 4, 2026
Launched interferon regulatory factor 5 (IRF5) program with preclinical data.
Recent news
Latest coverage and updates
- is_developingAug 18, 2026
HotSpot Therapeutics, Inc. is developing HST-2011.
- hiresAug 18, 2026
HotSpot Therapeutics, Inc. hired Niti Goel as Chief Medical Officer on Aug 18th '26.
- is_developingAug 18, 2026
HotSpot Therapeutics, Inc. is developing novel allosteric therapies for the treatment of autoimmune diseases.
HotSpot Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about HotSpot Therapeutics's valuation, stock price, and market status.
Is HotSpot Therapeutics a public or private company?
HotSpot Therapeutics is a private company.
What is the current stock price of HotSpot Therapeutics?
HotSpot Therapeutics is a private company, so its shares have no public market price. Caplight tracks HotSpot Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is HotSpot Therapeutics worth (valuation)?
Valuation information for HotSpot Therapeutics is not publicly available.
Can I buy HotSpot Therapeutics stock?
HotSpot Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was HotSpot Therapeutics's last funding round?
HotSpot Therapeutics's most recent funding round was Series C on November 29, 2021.
Who are the main investors in HotSpot Therapeutics?
Key investors in HotSpot Therapeutics include Pivotal bioVenture Partners, Nan Fung Group, Sofinnova Partners, Pivotal bioVenture Partners, Atlas Venture.
Will HotSpot Therapeutics IPO soon?
No public IPO plans have been announced for HotSpot Therapeutics.
How can I track HotSpot Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in HotSpot Therapeutics's shares on secondary markets.